GAD1 and Parkinson disease: Following the validation of the model reflecting a presymptomatic stage of PD, we assessed potential proVGF immunostaining changes in response to the development of pathological p-α-syn aggregates utilizing anti-TH, -proVGF C-terminus, and -GAD antibodies on SN and striatal sections.